Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bio Essence (BIOE) Common Equity (2020 - 2025)

Bio Essence has reported Common Equity over the past 6 years, most recently at -$2.1 million for Q4 2025.

  • For Q4 2025, Common Equity rose 30.18% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$2.1 million, up 30.18%, while the annual FY2025 figure was -$2.1 million, 30.18% up from the prior year.
  • Common Equity for Q4 2025 was -$2.1 million at Bio Essence, up from -$3.1 million in the prior quarter.
  • Over five years, Common Equity peaked at -$1.2 million in Q2 2023 and troughed at -$3.4 million in Q1 2023.
  • A 5-year average of -$2.5 million and a median of -$2.5 million in 2021 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: skyrocketed 59.24% in 2023 and later crashed 108.0% in 2025.
  • Year by year, Common Equity stood at -$2.4 million in 2021, then tumbled by 33.34% to -$3.2 million in 2022, then surged by 48.73% to -$1.7 million in 2023, then tumbled by 78.83% to -$3.0 million in 2024, then skyrocketed by 30.18% to -$2.1 million in 2025.
  • Business Quant data shows Common Equity for BIOE at -$2.1 million in Q4 2025, -$3.1 million in Q3 2025, and -$3.1 million in Q2 2025.